

## Documentation Checklist

Proper documentation includes recording the following in the medical record<sup>†</sup>:

<input type="checkbox"/> Most Recent Hb/Hct (include date)	<input type="checkbox"/> New EPOGEN <sup>®</sup> dose (if change required)
<input type="checkbox"/> Target Hb/Hct*	<input type="checkbox"/> Rationale for new EPOGEN <sup>®</sup> dose (if change required)
<input type="checkbox"/> Rationale for target Hb/Hct*	<input type="checkbox"/> Medical justification for patients whose physicians recommend Hb >12 g/dL*
<input type="checkbox"/> Current EPOGEN <sup>®</sup> dose	<input type="checkbox"/> Each EPOGEN <sup>®</sup> dose given, including nurse signature and title
<input type="checkbox"/> Documentation for each dose change	<input type="checkbox"/> <b>Physician's order with signature and date for each dose change<sup>†</sup></b>

If EPOGEN<sup>®</sup> dose is 10,000 units or higher, document the following additional information in narrative form<sup>†</sup>

<input type="checkbox"/> Patient's weight	<input type="checkbox"/> Blood loss, hemolysis, bone marrow dysplasia
<input type="checkbox"/> Current EPOGEN <sup>®</sup> dose required	<input type="checkbox"/> Refractory anemia due to nonrenal conditions (eg, aluminum toxicity)
<input type="checkbox"/> Historical record of EPOGEN <sup>®</sup> given	<input type="checkbox"/> Vitamin deficiencies
<input type="checkbox"/> Hb/Hct response to date	<input type="checkbox"/> Compromised bone marrow
<input type="checkbox"/> Iron indices	<input type="checkbox"/> Concomitant medications
<input type="checkbox"/> Concomitant conditions such as infection, inflammation, malignancy, or secondary hyperparathyroidism	

<sup>†</sup>These are general guidelines for appropriate documentation. Additional documentation may be required. For specific requirements that may vary by geographical region, please check with local regulatory and reimbursement agencies.

EPOGEN<sup>®</sup> is indicated for the treatment of anemia in patients with chronic renal failure on dialysis. Patients who receive EPOGEN<sup>®</sup> may experience adverse effects such as hypertension or flu-like symptoms. \*The EPOGEN<sup>®</sup> package insert recommends a target Hb (Hct) of 10 to 12 g/dL (30% to 36%). The NKF - K/DOQI™ guidelines recommend a target Hb (Hct) of 11 to 12 g/dL (33% to 36%).